Management of immune thrombocytopenia - Something old, something new

New England Journal of Medicine

Volumn 363, Issue 20, 2010, Pages 1959-1961

  George, James N ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; GLUCOCORTICOID; RECOMBINANT THROMBOPOIETIN; RITUXIMAB; ROMIPLOSTIM; FC RECEPTOR; HYBRID PROTEIN; THROMBOPOIETIN;

CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; HUMAN; INFECTION RISK; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; SIDE EFFECT; SPLENECTOMY; SURGICAL RISK; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT INDICATION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NOTE;

GLUCOCORTICOIDS; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; SPLENECTOMY; THROMBOPOIETIN;

EID: 79851482427     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1009141     Document Type: Editorial

References (10)

1. Doan CA, Bouroncle BA, Wiseman BK. Idiopathic and secondary thrombocytopenic purpura: clinical study and evaluation of 381 cases over a period of 28 years. Ann Intern Med 1960;53: 861-76.
2. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombo-cytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3-40. (Pubitemid 26230668)
3. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008;112:999-1004.
4. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic literature review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623-34. (Pubitemid 39434940)
5. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889-99.
6. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomized, phase 3 study. Lancet 2010 August 23 (Epub ahead of print).
7. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86.
8. Guidry JA, George JN, Vesely SK, Kennison SM, Terrell DR. Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol 2009;83:175-82.
9. Thomsen RW, Schoonen WM, Farkas DK, et al. Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Ann Intern Med 2009;151:546-55.
10. Thomsen RW, Schoonen WM, Farkas DK, Riis A, Fryzek JP, Sørensen HT. Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study. J Thromb Haemost 2010;8:1413-6.